Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update

Vigil Neuroscience, Inc. (NASDAQ:VIGL) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 681,400 shares, a decline of 18.4% from the November 30th total of 835,500 shares. Approximately 3.5% of the company’s shares are short sold. Based on an average daily volume of 190,300 shares, the days-to-cover ratio is currently 3.6 days.

Analyst Upgrades and Downgrades

VIGL has been the subject of a number of recent analyst reports. William Blair started coverage on Vigil Neuroscience in a research report on Wednesday, December 4th. They set an “outperform” rating for the company. Wedbush boosted their price objective on Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. HC Wainwright reiterated a “buy” rating and issued a $17.00 price target on shares of Vigil Neuroscience in a research note on Friday, November 8th. Finally, JMP Securities reiterated a “market outperform” rating and set a $22.00 target price on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $19.75.

Institutional Trading of Vigil Neuroscience

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Ensign Peak Advisors Inc increased its holdings in Vigil Neuroscience by 72.8% in the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock valued at $1,580,000 after buying an additional 166,442 shares in the last quarter. abrdn plc purchased a new position in Vigil Neuroscience during the 3rd quarter valued at about $799,000. Point72 Asset Management L.P. purchased a new stake in shares of Vigil Neuroscience in the second quarter valued at about $5,940,000. Verition Fund Management LLC acquired a new stake in Vigil Neuroscience during the 3rd quarter valued at $442,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Vigil Neuroscience in the second quarter valued at $87,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Vigil Neuroscience Trading Up 4.2 %

NASDAQ:VIGL opened at $1.72 on Monday. Vigil Neuroscience has a 12-month low of $1.54 and a 12-month high of $6.06. The firm has a market cap of $70.31 million, a P/E ratio of -0.83 and a beta of 1.65. The stock’s 50 day simple moving average is $2.80 and its 200-day simple moving average is $3.40.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.